Blog | HemaCare

Researchers Discover Antigen-Specific pTfh Cells in Patients with COVID-19

Feb 2, 2021 10:23:39 AM / by Stacy Matthews Branch, DVM, PhD posted in T Cells, Immunotherapy (Immunology)


Researchers found that follicular helper T-cells respond in different ways to structural proteins in COVID-19. They have been studying how the response happens over time.

Several studies report the observance of helper T-cell responses to the virus that causes COVID-19, SARS-CoV-2, in over 80% of individuals recovering from COVID-19. Besides helping in developing cytotoxic T cells, helper T cells stimulate B cells to produce antibodies. Therefore, T cells may help in the development of neutralizing antibodies against SARS-CoV-2.

Read More

HemaCare Macrophages Help Solve Mysteries of Immune Regulation

Jan 26, 2021 10:25:00 AM / by Nancy Andon, MSc posted in Cancer, Macrophages, Immunotherapy (Immunology)


The use of HemaCare-sourced macrophages has been cited in a recent publication in the Journal of Immunology. The paper is a collaboration between the University of Maryland in College Park, and biopharmaceutical company AstraZeneca. [1]

The role of macrophages in the human immune system is not nearly as well-known as T cells or B cells, which are seemingly ubiquitous in the cell and gene therapy field. Like lymphocytes, macrophages are derived from hematopoietic stem cells. Unlike the lymphoid lineage, however, myeloid precursors ultimately produce in the macrophage an immune cell capable of both antigen presentation and phagocytic activity.

Read More

Patients with Advanced Bladder Cancer May See Prolonged Survival with Immunotherapy

Dec 1, 2020 10:05:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, Immunotherapy (Immunology)


Published in the medical journal New England Journal of Medicine, a study found the proven drug, avelumab, may help the survival rate of those diagnosed with bladder cancer. 

According to the American Cancer Society, the 2020 United States estimates for bladder cancer cases are approximately 81,400 for new cases and 17,980 deaths. However, bladder cancer is a worldwide concern being the 13th most common cancer. Platinum-based chemotherapy is the standard-of-care for advanced urothelial carcinoma. Nevertheless, progression-free and overall survival are minimal with chemotherapy.

Read More

Combining Microbial Therapy with Immunotherapy May Help the Immune System Attack Cancer Cells

Nov 10, 2020 9:08:00 AM / by Stacy Matthews Branch, DVM, PhD posted in Cancer, T Cells, Immunotherapy (Immunology)


Researchers discovered how the gut microbiome helps our immune system fight tumors that are cancerous.

The gut microbiome has beneficial effects on health, and alterations in the microbiota can increase the risk of a number of illnesses. Past studies suggest that the gut microbiota can affect anti-tumor immunity, and recently, that it can be used to simulate the efficacy of immune checkpoint inhibitor therapy. Immune checkpoints are proteins that prevent immune cells from targeting and killing the body’s own cells. However, tumor cells can use these checkpoint proteins (CTLA-4, PD-1, or PD-L1) to evade the immune system’s attack.

Read More

HemaCare PBMCs Aid Development of Novel Cancer Immunotherapy

Aug 4, 2020 10:01:00 AM / by Nancy Andon, MSc posted in Cancer, PBMCs, Immunotherapy (Immunology)


A paper published in the journal Blood cites the use of HemaCare-sourced peripheral blood mononuclear cells (PBMCs) to test a murine model of a new antibody-based cancer immunotherapy.

Multiple myeloma (MM) is a life-threatening disease that accounts for 10-15% of all blood-based cancers. The disease occurs when a specific group of white blood cells, known as plasma cells, become malignant. T cell therapy has shown some promise in treating the disease on a temporary basis, but with very few cancer-specific targets identified, MM remains incurable.

Read More

      Subscribe Here!

      Posts by Topic

      see all

      Recent Posts